Physician profile
Albert E Kombe
NPI 1952937922
$2,772.91
in general payments reported to CMS, 2019-2025
21 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $858 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $435.19 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $267.32 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $241.54 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $234.54 | 2025 | |
| Amgen INC. | $143.18 | 2024-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $137.90 | 2024-2025 | Veozah |
| Insulet Corporation | $124.83 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.68 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $75.74 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $54.46 | 2025 | |
| Abbott Laboratories | $49.20 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.53 | 2025 | Caplyta |
| Radius Health, INC. | $32.58 | 2025 | Tymlos |
| Edwards Lifesciences Corporation | $30.51 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28.76 | 2024 | Auvelity |
| Currax Pharmaceuticals LLC | $28.73 | 2024-2025 | Contrave |
| Otsuka America Pharmaceutical, INC. | $18.57 | 2024 | Rexulti |
| Itamar Medical INC | $17.89 | 2025 | Watchpatone |
| Novartis Pharmaceuticals Corporation | $17.35 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.97 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Kombe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.